Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a specialty pharmaceutical innovator developing non-invasive therapies for central nervous system disorders and severe allergic reactions. This page serves as the definitive source for official company announcements, regulatory updates, and strategic developments.
Investors and industry stakeholders will find timely updates on product approvals, clinical trial milestones, licensing agreements, and financial performance. Our curated feed includes press releases related to Aquestive’s proprietary PharmFilm® technology, partnership expansions, and advancements in treatments like anaphylaxis management solutions.
All content is organized to provide clear insights into the company’s progress in addressing complex medical needs through innovative drug delivery systems. Key areas of coverage include FDA communications, research breakthroughs, and market expansion initiatives that underscore Aquestive’s role in reshaping patient care paradigms.
Bookmark this page for direct access to primary-source information about AQST’s scientific advancements and corporate strategy. Check regularly for updates that matter to your analysis of this pioneering healthcare company.
Aquestive Therapeutics will join the Russell 3000 and Russell 2000 Indexes, effective June 28, 2024, following the annual reconstitution of the Russell U.S. indexes. This inclusion highlights the company's achievements over the past year, including the successful completion of a Pivotal Study for Anaphylm (epinephrine) Sublingual Film, which met all primary and secondary endpoints, and FDA approval of Libervant (diazepam) Buccal Film for young epilepsy patients. Additionally, Aquestive raised $77.5 million from institutional healthcare investors. CEO Dan Barber emphasized that this milestone increases the company's visibility, awareness, and liquidity as they prepare for the potential market launch of their products, subject to FDA approval.
Aquestive Therapeutics (NASDAQ: AQST) has announced key executive appointments to boost its leadership team ahead of the anticipated launch of Anaphylm™ (epinephrine) Sublingual Film. Sherry Korczynski joins as Senior VP, Sales and Marketing, bringing over 20 years of experience, including roles at Mylan and ANI Pharmaceuticals. Dr. Stephen Wargacki is promoted to Chief Science Officer, having contributed significantly to the company's epinephrine prodrug platform since joining in 2015. Cassie Jung, with two decades at Aquestive, is named Chief Operating Officer, previously overseeing operations and CNS development. These strategic appointments aim to strengthen Aquestive's commercial capabilities and advance the launch of Anaphylm, potentially the first non-invasive epinephrine treatment for severe allergic reactions, pending FDA approval.
Aquestive Therapeutics will present data on Anaphylm™ (epinephrine) sublingual film at the 2024 Eastern Allergy Conference. The presentations will showcase positive pharmacokinetic and pharmacodynamic data from two clinical studies. The Phase 3 pivotal trial for Anaphylm met all expected endpoints, and the company plans to submit a New Drug Application to the FDA by the end of 2024. The conference will be held from May 30 to June 2 in Palm Beach, Florida, featuring experts in allergy, asthma, and immunology.
Aquestive's CEO Dan Barber expressed optimism about Anaphylm's potential to revolutionize severe allergic reaction treatments. The posters will be presented by Dr. Gary Slatko and Dr. David Golden on May 31.
Aquestive Therapeutics, Inc. (AQST) will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The management team will hold a fireside chat and host investor meetings. A webcast of the chat will be available on the company's website. For more information, visit investors.aquestive.com.
Aquestive Therapeutics reported positive results for their Phase 3 study on Anaphylm in Q1 2024, aiming for FDA approval by end of 2024. They also received FDA approval for Libervant for patients ages 2-5. The company extended their cash runway into 2026 through a public offering and continues to progress their pipeline development.
FAQ
What is the current stock price of Aquestive Therapeutics (AQST)?
What is the market cap of Aquestive Therapeutics (AQST)?
